Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | CKS1B | P61024 | 1/20 | 0.32 |
| ▸ | SKP1 | P63208 | 1/20 | 0.32 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12733833 | 0.92 | CSNK2A1 (0.35) | PAX8HCRTR1HCRTR2SSTR4PDE10A | |
| SCHEMBL14270690 | 0.91 | CYP4F2 (0.39) | PAX8BRD4HCRTR1HCRTR2CREBBP | |
| SCHEMBL31128424 | 0.91 | CYP4F2 (0.39) | PAX8BRD4HCRTR1HCRTR2CREBBP | |
| SCHEMBL12710241 | 0.90 | APP (0.40) | PAX8HCRTR1HCRTR2NQO2CKS1B | |
| SCHEMBL23131099 | 0.89 | PAX8 (0.40) | PAX8BRD4CREBBPSSTR4IRAK4 | |
| SCHEMBL12705243 | 0.88 | ACHE (0.39) | PAX8BRD4HCRTR1HCRTR2CREBBP | |
| SCHEMBL14182011 | 0.86 | PAX8 (0.40) | PAX8BRD4CREBBPIRAK4HTR2C | |
| SCHEMBL14270683 | 0.85 | PAX8 (0.39) | PAX8BRD4CREBBPSSTR4IRAK4 | |
| SCHEMBL8234289 | 0.85 | PAX8 (0.36) | PAX8BRD4HCRTR1HCRTR2CREBBP | |
| SCHEMBL22493865 | 0.85 | PAX8 (0.36) | PAX8BRD4HCRTR1HCRTR2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488513-B1 | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases | AC IMMUNE SA (CH) | 2017-12-27 | — | — | EP | disclosed |
| US-9701660-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE S.A. (CH) | 2017-07-11 | — | — | US | disclosed |
| US-9701660-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE S.A. (CH) | 2017-07-11 | — | — | US | disclosed |
| US-20150023950-A1 | 2,6-Diaminopyridine Compounds Suitable for Treating Diseases Associated with Amyloid or Amyloid-Like Proteins or for Treating or Preventing Ocular Diseases or Conditions Associated with a Pathological Abnormality/Change in the Tissue of the Visual System | AC IMMUNE S.A. (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20150023950-A1 | 2,6-Diaminopyridine Compounds Suitable for Treating Diseases Associated with Amyloid or Amyloid-Like Proteins or for Treating or Preventing Ocular Diseases or Conditions Associated with a Pathological Abnormality/Change in the Tissue of the Visual System | AC IMMUNE S.A. (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8916590-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE SA (CH) | 2014-12-23 | — | — | US | disclosed |
| US-8916590-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE SA (CH) | 2014-12-23 | — | — | US | disclosed |
| EP-1425010-B8 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | JANSSEN PHARMACEUTICALS INC (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-1425010-B1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110092537-A1 | 2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System | AC IMMUNE S.A. (CH) | 2011-04-21 | — | — | US | disclosed |
| EP-1218005-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2002060438-A1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| US-20020091264-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-07-11 | — | — | US | disclosed |
| EP-1218005-A2 | VITRONECTIN RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001017959-A2 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-15 | — | — | WO | disclosed |
| EP-1061921-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-27 | — | — | EP | disclosed |
| EP-1025090-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1025090-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999045927-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999015508-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092537-A1 | 2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System | APP, CLN6, DPYSL2 | PAX8 1986/4885BRD4 2805/4885HCRTR1 627/4885 |
| US-20020091264-A1 | Vitronectin receptor antagonists | CALCR, ADGRF1, CALCRL | PAX8 3175/4885BRD4 4476/4885HCRTR1 1555/4885 |
| US-20150023950-A1 | 2,6-Diaminopyridine Compounds Suitable for Treating Diseases Associated with Amyloid or Amyloid-Like Proteins or for Treating or Preventing Ocular Diseases or Conditions Associated with a Pathological Abnormality/Change in the Tissue of the Visual System | APP, CLN6, DPYSL2 | PAX8 1986/4885BRD4 2805/4885HCRTR1 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.